List of Excipients in Branded Drug FINASTERIDE

Generic Drugs Containing FINASTERIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	finasteride	0093-7355	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	finasteride	0093-7355	FD&C BLUE NO. 2
Teva Pharmaceuticals USA Inc	finasteride	0093-7355	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	finasteride	0093-7355	INDIGOTINDISULFONATE SODIUM

What are the Most Frequently-Used Excipients in FINASTERIDE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
104	CELLULOSE, MICROCRYSTALLINE
1	CI 77491
1	CI 77492

Finasteride Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

Finasteride is a mature, low-cost 5-alpha-reductase inhibitor with broad generic availability and no meaningful composition-of-matter exclusivity remaining in the United States. Commercial value has shifted from the active ingredient to differentiated delivery, tolerability, adherence, manufacturing efficiency, and regulated topical products. The strongest formulation opportunities are low-dose oral products, topical solutions or gels with controlled dermal delivery, pediatric or geriatric-friendly formats, and combination products that improve convenience without creating unnecessary regulatory risk.

What is finasteride used for, and which dosage forms are approved?

Finasteride is approved in two principal oral strengths:

Product	Strength	FDA indication	Original sponsor	FDA approval
Proscar	5 mg tablet	Benign prostatic hyperplasia	Merck	1992
Propecia	1 mg tablet	Male pattern hair loss	Merck	1997

Finasteride inhibits type II 5-alpha-reductase and lowers dihydrotestosterone formation. The 5 mg dose is used for prostate enlargement, while the 1 mg dose is used for androgenetic alopecia. Generic finasteride tablets are widely marketed in the United States and other major jurisdictions.[1,2]

The approved oral products are immediate-release, film-coated tablets. No FDA-approved long-acting injectable, implant, transdermal patch, or topical finasteride product was listed in the original U.S. approval framework through the FDA labels cited here.[1,2]

When did finasteride lose exclusivity?

Finasteride’s principal U.S. product and patent exclusivities expired years ago.

Milestone	Date or status
Proscar approval	1992
Propecia approval	1997
Core product and use patents	Expired
Generic 5 mg finasteride	Commercially established
Generic 1 mg finasteride	Commercially established
Current U.S. market	Multiple abbreviated new drug application products

Merck’s foundational finasteride patent family covered steroidal 5-alpha-reductase inhibitors, including finasteride. The main U.S. patent protection did not create a current barrier to generic entry. The FDA Orange Book lists approved finasteride products, but commercial entry is no longer dependent on challenging a live composition-of-matter patent.[3,4]

What is the Orange Book status of finasteride?

The Orange Book contains approved finasteride tablets in 1 mg and 5 mg strengths from multiple manufacturers. The relevant commercial issue is generally product approval, bioequivalence, manufacturing cost, and channel access rather than Paragraph IV litigation against an unexpired core patent.[3]

A new finasteride formulation can still receive patent protection if it claims a genuinely novel composition, delivery system, particle-size distribution, process, or combination. Such patents would not restore exclusivity to conventional tablets and would have to survive obviousness, enablement, written-description, and infringement scrutiny.

What excipients are used in finasteride tablets?

The reference products use conventional tablet excipients. The listed ingredients support powder flow, compression, disintegration, lubrication, and film coating.

Core oral excipient system

Typical excipient functions include:

Excipient class	Examples associated with reference-style finasteride tablets	Function
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and compressibility
Binder or dry binder	Pregelatinized starch, microcrystalline cellulose	Mechanical strength
Disintegrant	Sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and tooling protection
Glidant or antiadherent	Talc	Powder handling and processing
Surfactant or wetting aid	Docusate sodium	Wetting and dispersion
Film former	Hypromellose, hydroxypropyl cellulose	Coating integrity
Opacifier	Titanium dioxide	Appearance and light protection
Colorant	Aluminum lake pigments	Product identification

The exact inactive-ingredient profile varies by manufacturer and strength. DailyMed labeling should control for product-specific formulation analysis.[5]

What excipient constraints affect finasteride tablets?

Finasteride is a potent, low-dose drug in the 1 mg product. Content uniformity is therefore more important than tablet weight. Small segregation or blend-uniformity problems can produce a material dose deviation. Manufacturers should prioritize:

• geometric dilution or ordered mixing;
• low-segregation carrier selection;
• validated blend sampling;
• controlled lubricant addition;
• particle-size matching between API and diluents;
• low-shear processing where API agglomeration is a risk.

Lactose-based systems provide economical tablet manufacture, but lactose intolerance is generally not a significant clinical issue at the small quantities used in tablets. A lactose-free platform can still support market differentiation for selected consumer or institutional channels.

How should formulators select excipients for finasteride?

Finasteride is a lipophilic steroidal molecule with limited aqueous solubility. Its formulation challenge is not high-dose loading. It is achieving consistent dissolution and dose uniformity at low drug concentration.

Direct compression

Direct compression is the most attractive commercial platform for generic tablets when the API has acceptable flow and blend behavior. Microcrystalline cellulose, partially pregelatinized starch, mannitol, and low-substituted hydroxypropyl cellulose can be screened as alternatives to a lactose-heavy system.

A direct-compression formulation can reduce:

• granulation equipment requirements;
• processing time;
• solvent use;
• drying cost;
• manufacturing footprint.

The principal risks are poor content uniformity, tablet capping, lubricant sensitivity, and dissolution variability.

Wet granulation

Wet granulation is useful when the API has poor flow or when the formulation requires stronger tablets at low compression force. Povidone, pregelatinized starch, or hydroxypropyl cellulose can serve as binders. Aqueous granulation is generally preferred where feasible, but the process must control over-wetting, granule growth, and drug redistribution.

Wet granulation can improve blend uniformity but adds drying and scale-up complexity. It is more defensible commercially when it produces a measurable dissolution or content-uniformity advantage.

Solubility-enhancing systems

Potential approaches include:

• micronized API;
• nanocrystalline finasteride;
• amorphous solid dispersions;
• surfactant-assisted wetting;
• lipid-based self-emulsifying systems;
• cyclodextrin complexes;
• polymeric precipitation inhibitors.

These approaches can improve apparent dissolution, but the commercial value depends on whether the improvement changes bioequivalence, dose flexibility, food effect, shelf life, or patient adherence. A solubility technology that only accelerates dissolution without improving a clinically relevant product attribute may have limited market value.

What formulation patents could protect a finasteride product?

Expired basic patents do not prevent new formulation patents. The strongest claim categories are those tied to measurable product performance.

Formulation patent opportunities

Patent category	Potential claim focus	Commercial strength
Particle engineering	Defined particle-size distribution or crystalline form	Moderate
Solid dispersion	Polymer matrix, drug loading, dissolution profile	Moderate to strong if technically supported
Topical delivery	Solvent system, penetration enhancer, vehicle ratio	Moderate
Controlled release	Release profile and polymer architecture	Moderate
Combination therapy	Finasteride with minoxidil or another active	Moderate, but obviousness risk
Low-dose tablet	Blend uniformity and content-uniformity process	Weak to moderate
Taste-masked product	Coating or multiparticulate system	Moderate for pediatric or geriatric use
Manufacturing process	Specific granulation, drying, or coating sequence	Moderate if process materially improves quality

A patent strategy should claim composition, process, and performance in separate families. A single broad claim to “finasteride with a pharmaceutically acceptable excipient” is unlikely to provide durable protection because conventional excipient use is predictable.

What topical finasteride formulations offer commercial opportunities?

Topical finasteride is the most commercially relevant formulation opportunity because it targets the principal concern associated with oral therapy: systemic exposure and tolerability.

Potential vehicles include:

• hydroalcoholic solutions;
• hydrogels;
• emulgels;
• foams;
• liposomal systems;
• nanoemulsions;
• sprayable scalp products;
• polymeric films;
• microemulsion systems.

A topical product must balance local follicular delivery against systemic absorption. Excessive use of ethanol, propylene glycol, penetration enhancers, or occlusive vehicles can increase irritation and systemic exposure. A product with reduced systemic exposure, reproducible scalp deposition, and acceptable cosmetic properties has stronger commercial potential than a simple compounded solution.

What regulatory pathway applies to topical finasteride?

A manufacturer seeking a legally marketed topical product would generally need an FDA drug application supported by quality, nonclinical, clinical, and safety data. A compounded topical product does not automatically establish FDA approval or provide the same assurance of manufacturing consistency.

Topical finasteride also creates handling concerns. Women who are pregnant or may become pregnant should avoid contact with crushed or broken tablets because finasteride can affect development of male external genitalia. A topical product must address transfer, residual drug on the scalp, applicator design, packaging, labeling, and household exposure.[1,2]

How does topical finasteride compare with oral finasteride?

Attribute	Oral finasteride	Topical finasteride
Regulatory status	FDA-approved products	Product-specific regulatory status required
Dose consistency	High in approved tablets	Depends on formulation and applicator
Manufacturing complexity	Low	Moderate to high
Systemic exposure	Established	Must be characterized
Cosmetic acceptability	Not applicable	Critical
Patent opportunity	Limited for standard tablets	Higher for delivery systems
Generic competition	Intense	Less established
Commercial differentiation	Low	Potentially high

The business case for topical finasteride depends on demonstrated safety and reliable delivery, not only consumer interest. A topical product that produces inconsistent exposure or lacks controlled manufacturing may face medical, regulatory, and reputational barriers.

What combination products could create new finasteride opportunities?

The most obvious combination is finasteride with minoxidil for androgenetic alopecia. Combination opportunities include:

• fixed-dose oral finasteride and minoxidil;
• topical finasteride and minoxidil;
• finasteride with ketoconazole;
• finasteride with cosmetic scalp-care ingredients;
• finasteride with adherence-oriented digital dispensing systems.

A fixed-dose combination may improve adherence, but the patent position can be weak if the actives have known complementary use and the formulation is routine. Stronger protection requires evidence of an unexpected pharmacokinetic, tolerability, stability, or delivery benefit.

For benign prostatic hyperplasia, finasteride is also used with alpha blockers such as tamsulosin. The commercial opportunity is greater in simplified combination packaging or fixed-dose products than in new excipient selection alone. Combination-product development must account for dose flexibility and different dissolution requirements.

Which companies are challenging finasteride products?

Finasteride is a genericized market with multiple manufacturers rather than a concentrated Paragraph IV contest. Generic products have been marketed by companies including Teva, Dr. Reddy’s Laboratories, Aurobindo, Camber, Ascend, and other approved applicants, depending on strength and market period.[3,6]

The competitive landscape is divided into:

1. low-cost 5 mg tablets for BPH;
2. low-cost 1 mg tablets for hair loss;
3. mail-order and telehealth channels;
4. compounded topical products;
5. branded or private-label topical candidates;
6. combination hair-loss regimens.

Price competition is severe for standard oral tablets. A new entrant needs either a lower cost of goods, a differentiated route of administration, a better patient experience, or a distribution advantage.

What generic launch risks exist for finasteride?

The core generic-launch risk is not patent infringement. It is commercial commoditization.

Key risks include:

• reimbursement pressure;
• limited differentiation between tablet suppliers;
• API price volatility;
• content-uniformity failures at the 1 mg strength;
• dissolution failure after scale-up;
• coating defects and product-recognition issues;
• nitrosamine or elemental-impurity controls where applicable;
• tablet breakage and exposure warnings;
• pharmacy substitution dynamics;
• weak gross margins after wholesaler discounts.

A company pursuing a conventional tablet should use a low-cost, robust platform and avoid unnecessary excipients. A company pursuing a premium product should build the patent estate around delivery performance and patient-relevant outcomes.

How strong is the finasteride patent estate?

The conventional oral finasteride estate is weak because the key product and use patents have expired and numerous generic products are approved. New patent strength depends on claim specificity and technical evidence.

Estate component	Current strategic value
Core finasteride molecule	None as an exclusivity barrier
Standard 1 mg tablet	Low
Standard 5 mg tablet	Low
Novel topical vehicle	Moderate
Controlled follicular delivery	Moderate to strong if supported
New combination product	Moderate
Manufacturing process	Moderate
Packaging and applicator	Limited unless tied to safety or dosing
New indication	Potentially moderate, subject to clinical evidence

Freedom-to-operate analysis should review active formulation, process, topical-delivery, combination, and foreign patent families. Patent expiration should be assessed by jurisdiction because term adjustment, supplementary protection, national filing practices, and claim scope can differ.

What are the revenue and licensing opportunities?

Standard oral finasteride offers volume but limited pricing power. The best licensing targets are companies with:

• dermatology or hair-loss commercial infrastructure;
• topical formulation capabilities;
• validated transdermal or follicular-delivery platforms;
• telehealth distribution;
• experience with FDA drug applications;
• manufacturing capacity for low-dose tablets and semisolids.

Potential deal structures include an upfront payment for an exclusive topical formulation, milestone payments tied to FDA acceptance or approval, and royalties based on net sales. A license based only on a conventional tablet excipient blend is unlikely to command strong economics.

Commercial opportunity is highest when the product combines three attributes: a defensible delivery patent, a clear safety or convenience advantage, and access to a high-margin channel. A topical product that reduces systemic exposure while retaining efficacy could compete for premium pricing. A standard generic tablet generally cannot.

Key Takeaways

• Finasteride’s original oral product and use exclusivities have expired.
• Standard 1 mg and 5 mg tablets are highly commoditized.
• The main formulation challenge is low-dose content uniformity combined with limited aqueous solubility.
• Direct compression is the leading cost-efficient oral platform when blend uniformity is controlled.
• Topical finasteride offers the strongest formulation and licensing opportunity.
• Topical products require control of dermal delivery, systemic exposure, transfer risk, and cosmetic acceptability.
• Formulation patents should claim measurable delivery or performance benefits rather than routine excipient combinations.
• Combination products with minoxidil or BPH therapies may improve adherence but face obviousness and regulatory challenges.
• Commercial value is concentrated in differentiated delivery, premium distribution, and manufacturing efficiency.

FAQs About Finasteride Excipient Strategy

What is the best filler for a 1 mg finasteride tablet?

Microcrystalline cellulose, lactose monohydrate, mannitol, and pregelatinized starch are practical candidates. The selection should be based on blend uniformity, flow, compressibility, dissolution, and compatibility rather than filler cost alone.

Can finasteride be formulated as a sustained-release tablet?

Yes. Hydrophilic polymers, insoluble matrix formers, multiparticulates, or coated pellets can provide modified release. The commercial rationale is limited unless sustained release improves tolerability, adherence, or pharmacokinetic control.

Is topical finasteride protected by an active U.S. patent?

Protection depends on the specific vehicle, delivery system, process, and applicant. The expired patents covering conventional oral finasteride do not automatically eliminate patentability for a novel topical formulation.

Can finasteride and minoxidil be combined in one product?

Yes, technically. The principal development issues are chemical stability, pH, solubility, skin tolerability, dose uniformity, preservative selection, and the regulatory evidence required for the combined product.

What excipients are most important in a topical finasteride product?

The critical choices are the solvent system, penetration enhancer, gelling or thickening polymer, preservative, humectant, and packaging system. These components determine scalp deposition, irritation, systemic exposure, evaporation, and dose reproducibility.

References

1. U.S. Food and Drug Administration. (2022). Propecia (finasteride) tablets, 1 mg: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2022). Proscar (finasteride) tablets, 5 mg: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (1983). U.S. Patent No. 4,377,584: 4-aza steroids. USPTO.

5. National Library of Medicine. (2024). DailyMed: Finasteride tablet labeling and inactive ingredients. U.S. National Library of Medicine.

6. Drugs@FDA. (2024). Finasteride product approvals and application information. U.S. Food and Drug Administration.